CapsoVision heads into its November 12 report, due after the close, with the calendar finally catching up to its promises. Management said last quarter that US clearance for AI Highlights, its artificial intelligence reading tool, should arrive by the end of the third quarter. That is precisely the period now being reported. After one slip already, and an explicit warning that approval was not guaranteed, this release will show whether the company's AI story is moving forward in the United States or drifting further to the right.
The financial bar itself is modest. Analysts expect a loss of $0.15 per share, matching the prior quarter and slightly narrower than the $0.17 loss a year ago. Revenue is pegged at $3.8 million, up 7.4% from $3.5 million. That would be a step down from the 10% growth posted in the second quarter, when capsule shipments climbed 13%. Management guided second-half revenue above the first half, and with first-half sales totaling about $6.4 million, the consensus figure fits comfortably within that framing without requiring heroics. A clean beat on the top line would suggest the rebound from a soft first quarter was more than timing.
The operating metrics to watch are utilization and pricing. Patients imaged with CapsoCam Plus have risen every quarter, reaching 176,000 last period, up 23% from a year earlier, and recent renewals at University of Minnesota, Henry Ford, University of Colorado and Providence Swedish support the hospital-channel narrative. But growth in volume has been partly offset by price. Average selling prices fell roughly 3% last quarter as a named competitor pushed on pricing, and gross margin has slid from 55% a year ago to 51%, with inbound tariffs adding to costs. Another quarter of margin compression would signal that CapsoVision is buying share rather than earning it, which matters for a company that needs gross profit to carry a much heavier expense load.
That expense load is the other half of the tension. Operating costs jumped to $9.5 million last quarter from $6.5 million a year earlier, driven by clinical and engineering work, while cash fell to $9.1 million even after a $14 million raise. The new $100 million at-the-market equity program gives the company flexibility, but it also means shareholders should scrutinize the share count and any disclosure of ATM usage. Updates on the Colon Gen2 510(k) submission, now targeted for the fourth quarter, and early traction from the EU AI Highlights launch would help justify the spending.
The market has been fairly forgiving. Shares are up about 3% since the last report while the S&P 500 fell by a similar amount, and at $6.70 the stock sits above its 200-day moving average near the middle of its post-earnings range of $5.75 to $7.23. Sentiment, however, leans clearly bearish, suggesting many investors expect another regulatory delay or more dilution. That skepticism lowers the bar for a positive surprise on the FDA front.
Ultimately, this report comes down to whether CapsoVision can show regulatory execution alongside steady commercial growth. A US clearance, or at least firm evidence that it is imminent, paired with stable margins would validate the bull case. Another delay, combined with eroding pricing and a shrinking cash cushion, would leave the story looking increasingly dependent on fresh capital.